Keryx Pharmaceuticals Announces Upcoming Investor Presentations
29. Mai 2018 18:00 ET
|
Keryx Biopharmaceuticals, Inc.
BOSTON, May 29, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today...
Keryx Biopharmaceuticals Announces Data from an Investigator Sponsored Trial of Ferric Citrate in Patients with Advanced Chronic Kidney Disease in a Late-Breaking Presentation at the 55th Annual ERA/EDTA Today in Copenhagen
25. Mai 2018 06:00 ET
|
Keryx Biopharmaceuticals, Inc.
Conference Call Today at 8:30 a.m. EST COPENHAGEN, Denmark, May 25, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a company focused on bringing innovative medicines to...
Keryx Biopharmaceuticals Announces First Quarter 2018 Financial Results
10. Mai 2018 07:00 ET
|
Keryx Biopharmaceuticals, Inc.
First quarter 2018 total revenues of $21.7 million, including net U.S. Auryxia® (ferric citrate) product sales of $20.6 million; a 96 percent increase compared to the first quarter of 2017Company...
Keryx Biopharmaceuticals to Host Conference Call of First Quarter 2018 Financial Results on Thursday, May 10, 2018
07. Mai 2018 07:30 ET
|
Keryx Biopharmaceuticals, Inc.
BOSTON, May 07, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today...
Keryx Biopharmaceuticals Announces Changes to Management and Preliminary First Quarter 2018 Revenue
30. April 2018 08:00 ET
|
Keryx Biopharmaceuticals, Inc.
Gregory Madison resigned as president and chief executive officer of the company and from its board of directorsJodie Morrison, current Keryx board member, named interim chief executive officerCompany...
Keryx Biopharmaceuticals Announces Late-breaking Ferric Citrate Abstract Accepted for Presentation at the 55th ERA-EDTA Congress
19. April 2018 09:00 ET
|
Keryx Biopharmaceuticals, Inc.
BOSTON, April 19, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today...
Keryx Biopharmaceuticals Receives 2018 Corporate Innovator Award from the National Kidney Foundation
11. April 2018 09:11 ET
|
Keryx Biopharmaceuticals, Inc.
AUSTIN, Texas, April 11, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease,...
Keryx Biopharmaceuticals Announces Publication of Data from the Phase 3 Trial of Auryxia® (ferric citrate) for Iron Deficiency Anemia in Patients with Chronic Kidney Disease, Not on Dialysis, in the American Journal of Hematology
04. April 2018 08:00 ET
|
Keryx Biopharmaceuticals, Inc.
BOSTON, April 04, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today...
Keryx Biopharmaceuticals to Webcast its Presentation at the Cowen 38th Annual Healthcare Conference on March 12, 2018
06. März 2018 07:30 ET
|
Keryx Biopharmaceuticals, Inc.
BOSTON, March 06, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today...
Keryx Biopharmaceuticals Announces Fourth Quarter and Full Year 2017 Financial Results
07. Februar 2018 07:00 ET
|
Keryx Biopharmaceuticals, Inc.
Fourth quarter 2017 total revenues of $18.7 million, including net U.S. Auryxia® (ferric citrate) product sales of $17.3 millionFull year 2017 total revenues of $60.6 million; net U.S. Auryxia product...